The global precision medicine market size was valued at USD 106.7 billion in 2025 and is projected to grow from USD 121.71 billion in 2026 to USD 348.91 billion by 2034, registering a CAGR of 14.07% during the forecast period from 2026 to 2034. North America dominated the precision medicine market with a market share of 42.5% in 2025.
Precision medicine is an approach to healthcare that uses a person’s genetic, biological, environmental, and lifestyle information to guide more personalized prevention, diagnosis, and treatment. It helps healthcare providers select therapies based on individual patient characteristics rather than applying the same treatment broadly, particularly in areas such as cancer, rare diseases, and other complex conditions.
Download a Free Sample To learn more about this report,
Expansion of Genomic and Molecular Data in Clinical Decision-Making
Precision medicine is increasingly being built around genomic, molecular, clinical, and other health data to support more targeted prevention, diagnosis, and treatment. Advances in next-generation sequencing, molecular diagnostics, pharmacogenomics, and data analytics are strengthening the ability of healthcare providers to identify patient-specific disease characteristics and select more appropriate interventions.
Increasing Integration of AI With Precision Medicine
Artificial intelligence is becoming increasingly connected with genomics, diagnostics, risk stratification, and clinical decision-support systems. The combination of AI and large-scale health datasets can help identify disease patterns, support individualized treatment decisions, and improve the efficiency of precision-care pathways.
Growing Adoption of Targeted Therapies and Companion Diagnostics
The increasing development of therapies designed for specific molecular or genetic characteristics is driving demand for precision diagnostics that identify suitable patient populations. Companion diagnostics and next-generation sequencing enable clinicians to detect relevant biomarkers and match patients with targeted treatments, particularly in oncology and rare diseases.
High Infrastructure and Workforce Requirements Limit Wider Implementation
Precision medicine requires advanced laboratories, genomic testing capabilities, bioinformatics infrastructure, skilled professionals, and appropriate data-governance systems. These requirements can make implementation difficult in healthcare systems with limited resources and can create disparities in access between high-income and lower-resource settings.
Expansion of Individualized Therapies for Rare and Genetic Diseases
Advances in genome editing, RNA-based treatments, and molecular diagnostics are creating opportunities to develop therapies tailored to individual genetic conditions. Regulatory frameworks designed specifically for small patient populations could further support development where conventional large randomized trials are difficult to conduct.
Data Governance and Unequal Access Complicate Global Adoption
Precision medicine depends on large and diverse datasets, creating challenges related to privacy, ethical data use, interoperability, representation, and governance. Unequal access to genomic testing and advanced healthcare infrastructure can also limit the benefits of precision medicine and increase disparities between regions and population groups.
Precision Diagnostics Segment Dominated the Market with 31.5% Share in 2025
The precision diagnostics segment dominated the precision medicine market with a 31.5% share in 2025, reaching USD 33.61 billion, and is projected to grow at a CAGR of 12.18% during 2026–2034. Applied Sciences accounted for a 28.7% share, reaching USD 30.62 billion, while Precision Therapeutics represented 27.3%, reaching USD 29.13 billion. Digital Health and Information Technology accounted for a 12.5% share, reaching USD 13.34 billion, and is projected to grow at the fastest CAGR of 13.46%.
Precision diagnostics continues to lead because genomic testing, biomarker analysis, and molecular diagnostics are increasingly being used to identify disease characteristics and guide treatment decisions. Digital health and information technology are gaining momentum as healthcare providers increasingly use data analytics, connected platforms, and digital tools to support personalized care.
Request Customizationto receive a tailored report.
Oncology Segment Dominated the Market with 38.6% Share in 2025
The oncology segment dominated the precision medicine market with a 38.6% share in 2025, reaching USD 41.19 billion, and is projected to grow at a CAGR of 12.42% during 2026–2034. Neurology/psychiatry accounted for a 14.8% share, reaching USD 15.79 billion, while Infectious diseases represented 12.7%, reaching USD 13.55 billion. Cardiovascular accounted for 11.6%, Gastroenterology for 8.9%, Endocrinology for 7.4%, and Rheumatology for 6.0%.
Oncology remains the largest application because precision approaches can help identify molecular characteristics of tumors and support more targeted treatment selection. Growing use of genomic profiling, biomarker testing, and targeted therapies is further strengthening the role of precision medicine in cancer care. Other applications are also expanding as personalized approaches become increasingly relevant across chronic, neurological, infectious, and autoimmune diseases.
Speak to an Analystto discuss market opportunities.
North America dominated the precision medicine market with a 42.5% share in 2025, reaching USD 45.35 billion, and is projected to grow at a CAGR of 10.92% during 2026–2034. The region’s leading position is supported by advanced healthcare infrastructure, strong investment in genomics and molecular diagnostics, established pharmaceutical and biotechnology industries, and widespread adoption of personalized treatment approaches.
The US market is supported by strong research and development activity, advanced genomic testing capabilities, extensive clinical research, and the presence of major pharmaceutical and biotechnology companies. Increasing adoption of biomarker testing, targeted therapies, and data-driven clinical decision-making is also supporting market expansion.
Canada’s market is benefiting from growing investments in genomics, personalized healthcare programs, and advanced diagnostic technologies. Increasing integration of genomic information into healthcare and expanding access to precision-based testing are supporting the adoption of personalized medicine approaches.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe accounted for 26.4% of the precision medicine market in 2025, reaching USD 28.17 billion, and is projected to grow at a CAGR of 10.68% during 2026–2034. Growth is supported by established healthcare systems, government-backed genomics initiatives, increasing use of biomarker testing, and continued investment in advanced diagnostics and personalized therapies.
The UK market is supported by strong public healthcare infrastructure, genomics programs, and growing integration of genomic information into clinical care. Increasing adoption of molecular diagnostics and personalized treatment strategies is creating further opportunities across oncology and rare disease applications.
Germany’s market benefits from advanced healthcare infrastructure, strong pharmaceutical and biotechnology capabilities, and increasing use of genomic and molecular diagnostics. Growing interest in targeted therapies and personalized treatment approaches is also supporting market development.
Asia Pacific accounted for 21.8% of the precision medicine market in 2025, reaching USD 23.26 billion, and is projected to grow at the fastest CAGR of 14.37% during 2026–2034. Growth is supported by rising healthcare expenditure, expanding genomic testing capabilities, improving healthcare infrastructure, increasing disease burden, and growing government and private-sector investment in precision medicine.
China’s market is supported by expanding genomic research, increasing healthcare investment, and growing adoption of molecular diagnostics and personalized treatment approaches. The country’s large patient population and development of advanced healthcare technologies are creating significant opportunities for precision medicine applications.
Japan’s market is supported by an established healthcare system, advanced research capabilities, and growing demand for personalized approaches to cancer and chronic disease management. Increasing use of genomic information and advanced diagnostics is contributing to market growth.
Middle East and Africa accounted for 3.9% of the precision medicine market in 2025, reaching USD 4.16 billion, and is projected to grow at a CAGR of 10.84% during 2026–2034. Growth is supported by healthcare modernization, increasing investment in genomic technologies, rising awareness of personalized treatments, and efforts to strengthen advanced diagnostic capabilities.
Saudi Arabia’s market is supported by healthcare modernization programs, growing investment in genomics, and increasing adoption of advanced diagnostic technologies. National initiatives focused on genomic research and personalized healthcare are creating additional opportunities for market expansion.
South Africa’s market is supported by growing demand for advanced diagnostics and increasing research activity in genomics and molecular medicine. Improvements in healthcare infrastructure and greater awareness of targeted treatment approaches are gradually supporting precision medicine adoption.
The precision medicine market is competitive, with leading pharmaceutical, biotechnology, and genomics companies focusing on targeted therapies, genomic sequencing, companion diagnostics, biomarker discovery, and data-driven drug development. Key players include Bristol-Myers Squibb Company, Illumina Inc., AstraZeneca PLC, Eli Lilly and Company, Merck & Co. Inc., and QIAGEN N.V. Companies are increasingly strengthening their precision medicine capabilities through research collaborations, advanced genomic platforms, companion diagnostics, and AI-enabled drug discovery.
Illumina Inc.
Illumina Inc. is an important player in the precision medicine market, particularly through its genomic sequencing technologies and partnerships supporting biomarker discovery and companion diagnostics. The company is expanding the use of genomics, multi-omics, and artificial intelligence to help pharmaceutical companies identify genetic targets and develop more personalized treatment approaches.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanshee Bhapkar is a healthcare research professional with 4+ years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.
Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.
Chemotherapy Market Size, Share, Growth, Analysis, Report, 2034
Acute Spinal Cord Injury Market Size, Share, Growth, Analysis, 2034
Anti-Acne Treatment Market Size, Share, Growth, Analysis, 2034
Acne Treatment Market Size, Share & Growth Graph by 2034
Aesthetic Medicine Market Size, Share, Growth, Analysis, 2034
Anti-Osteoporosis Therapy and Fracture Healing Market Size, 2034
We are featured on:
sales@straitsresearch.com